Autoantibodies against islet cells (ICA), GAD, IA2, insulin

Pancreas (monkey)

Primate pancreas: Antibodies against islet cells
  • Detection of antibodies against islet cells of the pancreas (ICA).
  • Indication: Type I diabetes mellitus, differentiation between late manifestation of type 1 diabetes mellitus (latent autoimmune diabetes in adulthood, LADA) from type 2 diabetes.
  • For a reliable determination of antibodies against islet cells an extended incubation time of 18 hours for the patient serum must be observed. The incubation time may be reduced to 2 hours but this will lead to a decrease in the sensitivity of the antibody detection test.
  • Standardised control with JDF units available (order number CA 1021-0101-1).
  • With indirect immunofluorescence autoantibodies against pancreas islets (ICA) can be detected in 80% of patients with new-onset diabetes type 1. Characteristic target antigens of ICA are the enzyme glutamic acid decarboxylase (GAD) and tyrosine phosphatase (IA2).
  • This BIOCHIP can be supplemented by further substrates, e.g., primate cerebellum for detection of autoantibodies against GAD.
  • The use of small BIOCHIPs (1 x 1 mm) considerably facilitates the microscopic evaluation (order number FA 1020-1). The BIOCHIPS are virtually completely visible in the field of view, simplifying the location of the islet cells and, particularly for negative samples, eliminating the need for time-intensive examination.

ProductOrder number
Pancreas (monkey) BIOCHIPsFA 1020
Pancreas (monkey) and cerebellum (monkey) BIOCHIPsFA 1020-3

Anti-GAD, anti-IA2, anti-GAD/IA2 Pool

Incubated Anti-GAD ELISA
  • Monospecific detection of antibodies against glutamic acid decarboxylase (GAD), tyrosine phosphatase (IA2) or bispecific detection of both antibodies in a single reagent.
  • Indications: early diagnosis of type 1 diabetes mellitus, risk prediction in first grade relatives, prognosis of the clinical progression of type 1 diabetes for prediction of insulin dependence, differential diagnosis in gestational diabetes, differentiation between a late manifestation of type 1 diabetes (latent autoimmune diabetes in adulthood, LADA) and type 2 diabetes.
  • Use of undiluted samples. Similar incubation conditions and times. Manual or automated test performance.
  • Multipoint calibration. The quantitation is based on an international reference preparation (NIBSC 97/550).
  • GAD and IA2: human, recombinant antigens.
ELISA and RIA systems for the diagnosis of diabetes mellitus type I
ProductOrder number
Anti-GAD ELISAEA 1022 G
Anti-IA2 ELISAEA 1023 G
Anti-GAD/IA2 Pool ELISA  EA 1022-1 G

Anti-GAD, anti-IA2, anti-insulin

Anti-IA2 RIA
  • Monospecific detection of antibodies against glutamic acid decarboxylase (GAD), tyrosine phosphatase (IA2) and insulin.
  • Indications: Early diagnosis of type 1 diabetes mellitus type 1, risk prediction in first grade relatives, prognosis of the clinical progression of type 1 diabetes  for prediction of insulin dependence, differential diagnosis in gestational diabetes, differentiation between a late manifestation of type 1 diabetes (latent autoimmune diabetes in adulthood, LADA) and type 2 diabetes.
  • Use of undiluted samples. Similar incubation conditions and times. Manual or automated test performance.
  • Test kit formats for 50 or 100 determinations.
  • GAD and IA2: human, recombinant, 125I-labelled antigens, insulin: human, synthetic, 125I-labelled antigen.
     

ProductOrder number
Anti-GAD RIARA 1022
Anti-IA2 RIARA 1023
Anti-Insulin RIARA 1024